vs
Side-by-side financial comparison of BGC Group, Inc. (BGC) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
BGC Group, Inc. is the larger business by last-quarter revenue ($955.5M vs $619.8M, roughly 1.5× QuidelOrtho Corp). BGC Group, Inc. runs the higher net margin — 8.4% vs -14.8%, a 23.2% gap on every dollar of revenue. On growth, BGC Group, Inc. posted the faster year-over-year revenue change (43.8% vs -10.5%). Over the past eight quarters, BGC Group, Inc.'s revenue compounded faster (48.2% CAGR vs -6.6%).
BGC Group, Inc. is an American global financial services company based in New York City and London. Originally formed as part of the larger Cantor Fitzgerald organization, BGC Partners became its own entity in 2004.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
BGC vs QDEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $955.5M | $619.8M |
| Net Profit | $80.6M | $-91.8M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | 8.4% | -14.8% |
| Revenue YoY | 43.8% | -10.5% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.17 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $955.5M | $619.8M | ||
| Q4 25 | $638.6M | — | ||
| Q3 25 | $620.8M | $699.9M | ||
| Q2 25 | $648.0M | $613.9M | ||
| Q1 25 | $534.6M | $692.8M | ||
| Q4 24 | $475.2M | $707.8M | ||
| Q3 24 | $448.9M | $727.1M | ||
| Q2 24 | $435.0M | $637.0M |
| Q1 26 | $80.6M | $-91.8M | ||
| Q4 25 | $14.4M | — | ||
| Q3 25 | $27.9M | $-733.0M | ||
| Q2 25 | $57.5M | $-255.4M | ||
| Q1 25 | $55.2M | $-12.7M | ||
| Q4 24 | $25.2M | $-178.4M | ||
| Q3 24 | $14.7M | $-19.9M | ||
| Q2 24 | $37.8M | $-147.7M |
| Q1 26 | — | — | ||
| Q4 25 | 3.9% | — | ||
| Q3 25 | 5.4% | -100.7% | ||
| Q2 25 | 11.6% | -29.4% | ||
| Q1 25 | 15.0% | 4.7% | ||
| Q4 24 | 5.7% | -14.2% | ||
| Q3 24 | 4.4% | 2.1% | ||
| Q2 24 | 12.7% | -18.4% |
| Q1 26 | 8.4% | -14.8% | ||
| Q4 25 | 2.3% | — | ||
| Q3 25 | 4.5% | -104.7% | ||
| Q2 25 | 8.9% | -41.6% | ||
| Q1 25 | 10.3% | -1.8% | ||
| Q4 24 | 5.3% | -25.2% | ||
| Q3 24 | 3.3% | -2.7% | ||
| Q2 24 | 8.7% | -23.2% |
| Q1 26 | $0.17 | $-1.35 | ||
| Q4 25 | $0.03 | — | ||
| Q3 25 | $0.06 | $-10.78 | ||
| Q2 25 | $0.11 | $-3.77 | ||
| Q1 25 | $0.11 | $-0.19 | ||
| Q4 24 | $0.04 | $-2.54 | ||
| Q3 24 | $0.03 | $-0.30 | ||
| Q2 24 | $0.08 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $781.0M | $140.4M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $1.1B | $1.9B |
| Total Assets | $5.9B | $5.6B |
| Debt / EquityLower = less leverage | — | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $781.0M | $140.4M | ||
| Q4 25 | $851.5M | — | ||
| Q3 25 | $774.9M | $98.1M | ||
| Q2 25 | $827.8M | $151.7M | ||
| Q1 25 | $966.4M | $127.1M | ||
| Q4 24 | $711.6M | $98.3M | ||
| Q3 24 | $563.5M | $143.7M | ||
| Q2 24 | $571.7M | $107.0M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.8B | $2.5B | ||
| Q2 25 | $1.8B | $2.1B | ||
| Q1 25 | $1.1B | $2.1B | ||
| Q4 24 | $1.1B | $2.1B | ||
| Q3 24 | $1.4B | $2.2B | ||
| Q2 24 | $1.4B | $2.2B |
| Q1 26 | $1.1B | $1.9B | ||
| Q4 25 | $972.5M | — | ||
| Q3 25 | $965.3M | $2.0B | ||
| Q2 25 | $930.5M | $2.8B | ||
| Q1 25 | $963.8M | $3.0B | ||
| Q4 24 | $898.5M | $3.0B | ||
| Q3 24 | $860.1M | $3.2B | ||
| Q2 24 | $858.1M | $3.2B |
| Q1 26 | $5.9B | $5.6B | ||
| Q4 25 | $4.4B | — | ||
| Q3 25 | $5.8B | $5.7B | ||
| Q2 25 | $4.9B | $6.4B | ||
| Q1 25 | $4.9B | $6.5B | ||
| Q4 24 | $3.6B | $6.4B | ||
| Q3 24 | $4.4B | $6.8B | ||
| Q2 24 | $4.3B | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q4 25 | 1.58× | — | ||
| Q3 25 | 1.90× | 1.23× | ||
| Q2 25 | 1.97× | 0.74× | ||
| Q1 25 | 1.19× | 0.70× | ||
| Q4 24 | 1.27× | 0.72× | ||
| Q3 24 | 1.68× | 0.68× | ||
| Q2 24 | 1.68× | 0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BGC
| Commissions | $752.9M | 79% |
| Principal transactions | $142.9M | 15% |
| Data, network and post-trade | $34.5M | 4% |
| Other revenues | $10.3M | 1% |
| Fees from related parties | $4.3M | 0% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
